Citrate anticoagulation
The Citratantikoagulation is next to the heparinization of blood, a common form of anticoagulation in the dialysis . The advantage lies in their extracorporeal, local application. This means that patients can also be treated who cannot tolerate heparin ( HIT II , SHT ) or who are septic .
effect
By adding Ca complexing agents, e.g. B. citrate or EDTA , the calcium is bound as a chelate complex in the blood, preventing the blood from clotting. The calcium in the blood is therefore not available as a coagulation factor ("factor IV") and thus interrupts the coagulation process.
Detailed description
During an extracorporeal dialysis treatment, blood is pumped through a hose system and through a filter. This often leads to local coagulation, especially in the venous chamber or in the filter, so that it has to be blocked and replaced. This leads to longer treatment and blood loss for the patient.
A calcium complexing agent is now added to the arterial tube system directly after the access point; this now prevents blood clotting in the tube system. When blood is returned, the "free" calcium that has been partially filtered off is added to the vein directly in front of the patient access. The calcium complexing agent is metabolized to bicarbonate in the systemic circulation in the liver, kidneys and skeletal muscles and the inhibition is thus canceled.
Many dialysis machines now support this method and offer a corresponding process with integrated pumps and controls.
Individual evidence
- ↑ Ci-Ca Anticoagulation FMC (as of March 7, 2014).
- ↑ Ci-Ca Therapy european hospital ( Memento of the original from March 9, 2014 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. (As of March 7, 2014).
- ↑ Brochure Ci-Ca Anticoagulation with multiFiltrate
